aXichem announces indicative positive data from trail, regarding phenylcapcaisin’s effect on sports performance in athletes, carried out at University of Pablo Olavide, Spain
aXichem AB (publ), a developer of natural analogue industrial compounds and a leading neutraceuticals ingredient provider, today announces first indicative positive results from a finalized trial including aXivite®. The trial’s aim was to determine the effect of phenylcapsaicin and to evaluate its effect on electrical muscle activity, biochemical responses, and neuromuscular performance. The trial was conducted in collaboration with aXichem’s partners LIFEPro Nutritionand Indiex Sport Nutrition, together with University of Valencia and Pablo de Olavide University.
The trial is now finalized, and the first phase of data analysis is concluded. The initial results have a high scientific relevance for sport nutrition and sport performance, and they will be published in a high-impact journal of sport science.
“I am thrilled to see these first exciting results from the trial. Together with our Spanish partners LIFEPro Nutrition and Indiex Sport Nutrition I am looking forward to the final study report which we expect will be ready, and published by the investigators, in a few months. I believe that aXivite has a huge potential in many sports segment as a pre workout unique formulation, says Lucas Altepost, VP and Chief Sales and Marketing Officer at aXichem.
In addition, Pablo Jiménez and Carlos Alix, research directors of the project, declared: “Capsaicinoids are the future of ergogenic aids in different disciplines due to their unique molecular mechanisms. The results of this trial were greater than what we expected in the first meeting. We are very excited regarding the publication of these results. Moreover, it has been a pleasure working with our Swedish partners of aXichem. We are sure that this trial is the start of a promising path together.”
More about the study
Oral capsaicinoids and capsinoids supplements have previously been studied for a plausible ergogenic impact on sports performance. The purpose of this experimental research has been to explore the effects of phenylcapsaicin on resistance training. As aXichem’s phenylcapsaicin is more bioavailable than natural capsaicin, the study, carried out under aXichem’s collaboration with LIFEPro and Indiex, was designed as a three-branched, randomized, triple-blinded, placebo-controlled, crossover trial. In the trial, biochemical parameters related to muscle damage, metabolic response and myoelectrical variables was measured. Sport performance outcomes was related to some of the most validated tests, well proven in trials of this kind. 30 healthy, highly trained male athletes, with previous experience from trials and test situations took part in the trial, that conducted at Universidad Pablo Olavide (UPO), Seville, Spain, in collaboration with University of Valencia, Madrid Autonomous University and National School of Strength and Physical Conditioning (ENFAF) researchers.
Indiex Sport Nutrition is one of Spain’s leading manufacturers and suppliers of nutrition products, specifically targeting the market for sports and fitness. Indiex has direct sales to consumers as well as to resellers with known brands such as LifePro Nutrition in their portfolio.
More about aXivite®
aXivite is a natural analogue product, developed to fit as a component in food supplement and nutrition products. aXivite is an adjusted version of aXichem’s synthetically produced and patented capsacin, aXiphen®. Since the product is synthetically produced the substance has several advantages compared to natural capsaicin. The main difference is that natural capsaicin is extracted from chili and therefore varies in quality and seldom reaches a concentration above 85 percent. aXiphen® holds a concentration of at least 97 percent and has predictable characteristics. One of the key industrial benefits with the product is that aXichem can determine its water- and fat solubility, which is critical when using the substance in various kinds of products. aXiphen has a GRAS food clearance in the U.S. and a Novel Food approval for the EU.
This information is such that aXichem AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the contact person, for publication on September 29, 2022, at 08:30 AM CEST.
Torsten Helsing, CEO, aXichem, Ph+46 70 686 33 55. Email: [email protected]
aXichem’s business idea is to develop, patent and market natural analogue industrial compounds. The Company primarily works with phenylcapsaicin a structural analogue of capsaicin with a wide range of applications, such as feed additives, nutrition and supplements, marine anti-fouling products and certain pharmaceutical areas. aXichem’s shares are listed on NASDAQ First North Growth Market under AXIC A. Certified Adviser: Redeye AB. Read more about aXichem at www.axichem.se
RLS Global: Emissionen registrerad och handeln med BTA upphör
RLS Global AB (publ) (”RLS Global” eller ”Bolaget”) har genomfört en företrädesemission av aktier som avslutades den 11 november 2022. Företrädesemissionen är nu registrerad vid Bolagsverket och sista dag för handel med betald tecknad aktie (”BTA”) är onsdag den 14 december 2022. Avstämningsdag är 1...
RLS Global: The rights issue is registered and the trading in Paid Subscription Shares ceases
RLS Global AB (publ) (”RLS Global” or "the Company”) has completed a rights issue of shares that closed on 11 November, 2022. The rights issue is now registered with the Swedish Companies Registration Office and the last day for trading in paid subscribed shares ("BTA") will be Wednesday, December 1...
Nexstim Receives an NBS System Order from a Hospital in Poland
This is Nexstim’s first sale to Poland. The system will be used for performing neurosurgery planning in patients that have had a diagnosis of a brain tumor or other disorder. The Nexstim NBS System is the only FDA cleared and CE-marked navigated TMS system for pre-operative mapping of the motor and...
Diagonal Bio AB tillkännager initial detektionsgräns (LoD) för Panviral i linje med PCR standard
Diagonal presenterar idag nya testresultat för Panviral-systemets LoD för detektion av syntetisk influensa RNA. Testet utfördes med den senaste versionen av Panviral ämnad för forskningsändamål (Instrument for Research Use Only, RUO) samt Cartridge och ReactionMix...